Literature DB >> 10075948

Proteolytic release of membrane bound intercellular regulators.

V E Eysselein1.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10075948      PMCID： PMC1727451          DOI： 10.1136/gut.44.4.454

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  7 in total

1.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

2.  Mice lacking transforming growth factor alpha have an increased susceptibility to dextran sulfate-induced colitis.

Authors:  B Egger; F Procaccino; J Lakshmanan; M Reinshagen; P Hoffmann; A Patel; W Reuben; S Gnanakkan; L Liu; L Barajas; V E Eysselein
Journal:  Gastroenterology       Date:  1997-09       Impact factor: 22.682

3.  TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice.

Authors:  N C Luetteke; T H Qiu; R L Peiffer; P Oliver; O Smithies; D C Lee
Journal:  Cell       Date:  1993-04-23       Impact factor: 41.582

4.  Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation.

Authors:  G B Mann; K J Fowler; A Gabriel; E C Nice; R L Williams; A R Dunn
Journal:  Cell       Date:  1993-04-23       Impact factor: 41.582

5.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; J R Kalden; C Antoni; J S Smolen; B Leeb; F C Breedveld; J D Macfarlane; H Bijl
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

6.  Reduced susceptibility of mice overexpressing transforming growth factor alpha to dextran sodium sulphate induced colitis.

Authors:  B Egger; H V Carey; F Procaccino; N N Chai; E P Sandgren; J Lakshmanan; V S Buslon; S W French; M W Büchler; V E Eysselein
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

7.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

Authors:  H M van Dullemen; S J van Deventer; D W Hommes; H A Bijl; J Jansen; G N Tytgat; J Woody
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.